LCM
XFOR icon

Laurion Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Laurion Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-83
Closed -$191K – 1746
2017
Q4 		$191K Buy
+83
New +$210K ﹤0.01% 1444

Other funds holding XFOR

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Laurion Capital Management's XFOR Position: Q1 2018 in Review

Laurion Capital Management sold out of X4 Pharmaceuticals (XFOR) in Q1 2018, closing a stake of 83 shares — an estimated $191K sold.

Laurion Capital Management first reported a position in XFOR in Q4 2017 and held it in 1 quarter. The position peaked at $191K in Q4 2017. 35 funds tracked by Wall St. Rank hold XFOR as of Q1 2018.

  • Laurion Capital Management reported no remaining X4 Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Laurion Capital Management sold 83 X4 Pharmaceuticals shares in Q1 2018, an estimated $191K.
  • Laurion Capital Management first reported a position in X4 Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Laurion Capital Management's X4 Pharmaceuticals position peaked at $191K in Q4 2017.
  • 35 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2018.

Based on Laurion Capital Management's 13F filing for Q1 2018, filed 14 May 2018.